We claim:

1. A compound of the formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;

R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;

R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein X is O.

3. A compound according to claim 1 wherein X is S.

4. A compound according to any one of claims 1 to 3 wherein R_2 is H.

5. A compound according to any one of claims 1 to 4 wherein n is 2.

6. A compound according to any one of claims 1 to 5 wherein R_3 is H.

7. A compound according to any one of claims 1 to 5 wherein R_3 is methyl.

8. A compound according to any one of claims 1 to 7 wherein R_4 is 2-pyridyl.

9. A compound according to any one of claims 1 to 8 wherein ------ is a double bond.

10. A compound according to any one of claims 1 to 9 wherein Y is –CO-.

11. A compound which is selected from the group consisting of:

a) 4-(6-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one;

b) 4-(5-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one;

c) 4-(2-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one; and

d) 4-(3-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one; or a pharmaceutically acceptable salt thereof.

12. A method of inhibiting the reuptake of serotonin and antagonizing the 5-HT_{1A} receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of the formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;
R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;
R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;
R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;
R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;
or a pharmaceutically acceptable salt thereof.

13. A method of potentiating the action of a serotonin reuptake inhibitor comprising administering to a subject in of such treatment a compound formula:



wherein:
W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

heterocycle substituted with from 1 to 3 substituents selected from the group

consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;

R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;

R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

or a pharmaceutically acceptable salt thereof.

14. A method of treating depression comprising administering to a subject in need thereof an effective amount of a compound of formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;

R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;

R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising an effective amount of a compound as claimed in any one of claims 1 to 11 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

16. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for inhibiting the reuptake of serotonin, antagonizing the 5-HT_{1A} receptor, and antagonizing the 5-HT_{2A} receptor.

17. The use of a compound as claimed in any one of claims 1 to 11 for inhibiting the reuptake of serotonin, antagonizing the 5-HT_{1A} receptor, and antagonizing the 5-HT_{2A} receptor.

18. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment of depression.

19. The use of a compound as claimed in any one of claims 1 to 11 for the treatment of depression.

20. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 11 for use in the treatment of depression.